Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans

Poetsch, Joseph H.; Dahlke, Christine; Zinser, Madeleine E.; Kasonta, Rahel; Lunemann, Sebastian; Rechtien, Anne; Ly, My L.; Stubbe, Hans C.; Kraehling, Verena; Biedenkopf, Nadine; Eickmann, Markus; Fehling, Sarah K.; Olearo, Flaminia; Strecker, Thomas; Sharma, Piyush; Lang, Karl S.; Lohse, Ansgar W.; Schmiedel, Stefan; Becker, Stephan; Siegrist, Claire-Anne; Huttner, Angela; Addo, Marylyn M.; Bejon, Phillip; Njuguna, Patricia; Ndungu, Francis; Kremsner, Peter G.; Brosnahan, Jessica S.; Agnandji, Selidji Todagbe; Krishna, Sanjeev; Kieny, Marie Paule; Modjarrad, Kayvon; Moorthy, Vasee; Fast, Patricia; Savarese, Barbara and Lapujade, Olivier (2019): Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans. In: Journal of Infectious Diseases, Vol. 219, No. 4: pp. 556-561

Abstract

In response to the Ebola virus (EBOV) crisis of 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV vector are available. Within the scope of a phase 1 study, we performed a comprehensive longitudinal analysis of adaptive immune responses to internal VSV proteins following VSV-EBOV immunization. While no preexisting immunity to the vector was observed, more than one-third of subjects developed VSV-specific cytotoxic T-lymphocyte responses and antibodies.

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health
• ISSN: 0022-1899
• Language: English